Pfizer and BioNTech seek FDA EUA for Omicron-based Covid-19 vaccine
Pharmaceutical Technology
AUGUST 23, 2022
Pfizer and BioNTech have filed an application seeking Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for a booster dosage of an Omicron BA.4/BA.5-adapted 1-adapted vaccine. 5-adapted bivalent vaccine for Covid-19 in people aged 12 years and above. 5 and the wild-type viral strain.
Let's personalize your content